GermanyOverall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Dermatology & Venereal Diseases
Rank in SubField 1: 4,874 out of 355,674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 129,365 | 136,246 |
| Total Cites | 26,824 | 30,554 |
| H-index | 70 | 74 |
| Hm-index | 18 | 19 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 66 | 66 |
| Total Cites to Single+First Authored Papers | 2,088 | 2,363 |
| Number of Single+First+Last Authored Papers | 171 | 171 |
| Total Cites to Single+First+Last Authored Papers | 4,997 | 5,691 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 20,157 | 21,763 |
| Ratio of Total Citations to Distinct Citing Papers | 1.33 | 1.40 |
| Self-Citation Percentage |
12.21%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Dermatology & Venereal Diseases
Rank in SubField 1: 5,083 out of 334,837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 134,021 | 140,066 |
| Total Cites | 23,478 | 26,790 |
| H-index | 65 | 68 |
| Hm-index | 17 | 19 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 64 | 64 |
| Total Cites to Single+First Authored Papers | 1,886 | 2,143 |
| Number of Single+First+Last Authored Papers | 163 | 163 |
| Total Cites to Single+First+Last Authored Papers | 4,521 | 5,158 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 17,819 | 19,262 |
| Ratio of Total Citations to Distinct Citing Papers | 1.32 | 1.39 |
| Self-Citation Percentage |
12.36%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Dermatology & Venereal Diseases
Rank in SubField 1: 5,225 out of 312,644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 137,210 | 142,564 |
| Total Cites | 20,210 | 23,125 |
| H-index | 61 | 66 |
| Hm-index | 17 | 18 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 61 | 61 |
| Total Cites to Single+First Authored Papers | 1,673 | 1,905 |
| Number of Single+First+Last Authored Papers | 151 | 151 |
| Total Cites to Single+First+Last Authored Papers | 4,053 | 4,653 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 15,438 | 16,733 |
| Ratio of Total Citations to Distinct Citing Papers | 1.31 | 1.38 |
| Self-Citation Percentage |
12.61%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Dermatology & Venereal Diseases
Rank in SubField 1: 5,488 out of 293,195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 144,672 | 150,826 |
| Total Cites | 16,608 | 19,103 |
| H-index | 55 | 58 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 59 | 59 |
| Total Cites to Single+First Authored Papers | 1,443 | 1,643 |
| Number of Single+First+Last Authored Papers | 143 | 143 |
| Total Cites to Single+First+Last Authored Papers | 3,579 | 4,132 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 12,890 | 14,014 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.36 |
| Self-Citation Percentage |
13.06%
|
|
Trending Researchers
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.